- Sonoma Pharmaceuticals Inc SNOA has launched Microdox, an urinary tract infection catheter and bladder rinse in New Zealand, Australia, and South Africa.
- Microdox is a super-oxidized solution based on Sonoma's patented Microcyn Technology intended to treat and prevent infections in the urinary tract and bladder.
- Microdox is a non-irritating and non-toxic solution and is ready for immediate use. It is currently available through Sonoma's partners, Te Arai BioFarma in New Zealand and Australia, and NuAngle in South Africa.
- Also See: Sonoma Pharma Expands Its Partner Network For Oral, Dental Products In US & China.
- "We believe Microdox is a unique bladder irrigation that fulfills the requirements of an effective adjunct UTI prevention and treatment for removing UTI-causing bacteria, bacterial biofilms, and drug-resistant strains," said Scott Lissington, COO of Te Arai BioFarma.
- Price Action: SNOA shares are up 8.33% at $3.64 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in